文献速递肺栓塞与肺血管病间质性肺疾病

弥散功能与超声心动图参数识别系统性硬化症轻度肺动脉高压

Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis.
PubMed 文献 · Chest · 2024-06-06

基于EUSTAR数据库纳入同时具备TAPSE、sPAP与mPAP数据的系统性硬化症患者,比较各筛查参数识别右心导管mPAP 21~24 mm Hg者的诊断效能。结果显示DLCO<80%预计值敏感性(88.9%)与阴性预测值(80%)最高但特异性(18.2%)与阳性预测值(30.8%)最低,TAPSE/sPAP<0.55 mm/mm Hg特异性(78.9%)、阳性预测值(50%)与准确率(68.1%)最高。

要点

  • DLCO<80%预计值适合初筛排除,敏感性88.9%、阴性预测值80%。
  • TAPSE/sPAP<0.55 mm/mm Hg特异性78.9%、准确率68.1%,可减少不必要右心导管。
  • mPAP 21~24 mm Hg组TAPSE/sPAP低于非PH组,其余参数两组无差异。

核心结论

  • DLCO<80%预计值在识别系统性硬化症合并mPAP 21~24 mm Hg患者时敏感性及阴性预测值最高。
  • TAPSE/sPAP<0.55 mm/mm Hg特异性、阳性预测值与准确率最高,可作为减少不必要右心导管的附加参数。

研究设计与样本

  • 基于欧洲硬皮病试验与研究(EUSTAR)数据库的系统性硬化症患者分析。
  • 纳入具备TAPSE、sPAP与mPAP数据的患者,比较mPAP 21~24 mm Hg组与mPAP≤20 mm Hg组。
  • 计算敏感性、特异性、阳性预测值、阴性预测值与准确率。

主要发现

  • mPAP 21~24 mm Hg组TAPSE/sPAP为0.58(0.46-0.72)mm/mm Hg,低于非PH组的0.69(0.57-0.81)mm/mm Hg,P<.01。
  • 两组间其他参数未见差异。
  • DLCO<80%预计值敏感性88.9%、阴性预测值80%、特异性18.2%、阳性预测值30.8%。
  • TAPSE/sPAP<0.55 mm/mm Hg特异性78.9%、阳性预测值50%、准确率68.1%、阴性预测值75.4%、敏感性45.1%。

关键数值与推荐

  • 肺动脉高压定义为右心导管静息mPAP>20 mm Hg(2022 ESC/ERS指南)。
  • mPAP 21~24 mm Hg为既往「灰区」范围。
  • TAPSE/sPAP<0.55 mm/mm Hg为本文评估的筛查阈值。
  • DLCO<80%预计值为本文评估的筛查阈值。

临床怎么用

  • 对系统性硬化症患者可先用DLCO<80%预计值初筛,其高敏感性有助于排除。
  • 对初筛阳性者结合TAPSE/sPAP<0.55 mm/mm Hg提高特异性,减少不必要的右心导管。
  • mPAP 21~24 mm Hg人群的筛查策略需综合弥散功能与超声心动图参数判断。

局限性

  • 原文摘要未报告研究样本量。
  • 原文摘要未报告研究的具体局限性说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2022 European Society of Cardiology/European Respiratory Society guidelines define pulmonary hypertension (PH) as a resting mean pulmonary artery pressure (mPAP) > 20 mm Hg at right heart catheterization (RHC). Previously, patients with an mPAP between 21 and 24 mm Hg were classified in a "gray zone" of unclear clinical significance. RESEARCH QUESTION: What is the diagnostic performance of the main parameters used for PH screening in detecting patients with systemic sclerosis (SSc) with an mPAP of 21 to 24 mm Hg at RHC? STUDY DESIGN AND METHODS: Patients with SSc from the European Scleroderma Trials and Research (EUSTAR) database with available tricuspid annular plane systolic excursion (TAPSE), systolic PAP (sPAP), and mPAP data were included. Patients with mPAP 21 to 24 mm Hg and patients with mPAP ≤ 20 mm Hg were considered for the analysis. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated. RESULTS: TAPSE/sPAP was lower in the group of patients with SSc with mPAP 21 to 24 mm Hg than in the non-PH group (0.58 [0.46-0.72] vs 0.69 [0.57-0.81] mm/mm Hg, respectively; P < .01). No difference was found in other parameters between the two groups. Diffusing capacity of the lungs for carbon monoxide < 80% of the predicted value had the highest sensitivity (88.9%) and NPV (80%), but the lowest specificity (18.2%) and PPV (30.8%) in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP < 0.55 mm/mm Hg had the highest specificity (78.9%), PPV (50%), and accuracy (68.1%); its NPV was 75.4%, and its sensitivity was 45.1%. INTERPRETATION: In this study, diffusing capacity of the lungs for carbon monoxide < 80% of the predicted value was the parameter with the highest sensitivity and NPV in detecting patients with SSc with mPAP 21 to 24 mm Hg. TAPSE/sPAP < 0.55 mm/mm Hg had the highest specificity, PPV, and accuracy and, therefore, can be a useful additional parameter to decrease the number of unnecessary RHCs.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Colalillo A, Hachulla E, Pellicano C, et al. Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis. Chest. 2024. PMID: 38849072. doi:10.1016/j.chest.2024.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。